Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system
Yuyong Zhou, Karen Anbro Gammeltoft, Line A. Ryberg, et al.
Science Advances (2022) Vol. 8, Iss. 51
Open Access | Times Cited: 165

Showing 1-25 of 165 citing articles:

The evolution of SARS-CoV-2
Peter V. Markov, Mahan Ghafari, Martin Beer, et al.
Nature Reviews Microbiology (2023) Vol. 21, Iss. 6, pp. 361-379
Open Access | Times Cited: 703
Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir
Yanmei Hu, Eric M. Lewandowski, Haozhou Tan, et al.
ACS Central Science (2023) Vol. 9, Iss. 8, pp. 1658-1669
Open Access | Times Cited: 204
The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir
Dirk Jochmans, Liu C, Kim Donckers, et al.
mBio (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 127
Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors
Seyed Arad Moghadasi, Emmanuel Heilmann, Ahmed Magdy Khalil, et al.
Science Advances (2023) Vol. 9, Iss. 13
Open Access | Times Cited: 126
Small molecules in the treatment of COVID-19
Sibei Lei, Xiaohua Chen, Jieping Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 78
Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir
Yanmei Hu, Eric M. Lewandowski, Haozhou Tan, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 75
Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance
Jonathan Daniel Ip, Allen Wing‐Ho Chu, Wan-Mui Chan, et al.
EBioMedicine (2023) Vol. 91, pp. 104559-104559
Open Access | Times Cited: 67
Therapeutics for COVID-19
Sima S. Toussi, Jennifer Hammond, Brian S. Gerstenberger, et al.
Nature Microbiology (2023) Vol. 8, Iss. 5, pp. 771-786
Open Access | Times Cited: 66
Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China
Liyan Yang, Zhonglei Wang
European Journal of Medicinal Chemistry (2023) Vol. 257, pp. 115503-115503
Open Access | Times Cited: 63
Sequential intrahost evolution and onward transmission of SARS-CoV-2 variants
Ana S. González-Reiche, Hala Alshammary, Sarah Schaefer, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 57
Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review
Xin Li, Yongcheng Song
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115772-115772
Open Access | Times Cited: 51
A new generation Mpro inhibitor with potent activity against SARS-CoV-2 Omicron variants
Chong Huang, Huiping Shuai, Jingxin Qiao, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 49
Multidrug-resistant mutations to antiviral and antibody therapy in an immunocompromised patient infected with SARS-CoV-2
Yosuke Hirotsu, Hiroaki Kobayashi, Yumiko Kakizaki, et al.
Med (2023) Vol. 4, Iss. 11, pp. 813-824.e4
Open Access | Times Cited: 49
Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study
Carlos King Ho Wong, Kristy T. K. Lau, Ivan Chi Ho Au, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 6, pp. 683-695
Open Access | Times Cited: 45
In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir
Maki Kiso, Seiya Yamayoshi, Shun Iida, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 39
A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir
Jacqueline G. Gerhart, Donna S. Cox, Ravi Shankar Prasad Singh, et al.
Clinical Pharmacokinetics (2024) Vol. 63, Iss. 1, pp. 27-42
Open Access | Times Cited: 20
Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19
Long Mao, Namir Shaabani, Xiaoying Zhang, et al.
Med (2024) Vol. 5, Iss. 1, pp. 42-61.e23
Open Access | Times Cited: 17
SARS-CoV-2 Drug Resistance and Therapeutic Approaches
Sania Batool, Santosh Chokkakula, Ju Hwan Jeong, et al.
Heliyon (2025) Vol. 11, Iss. 2, pp. e41980-e41980
Open Access | Times Cited: 3
Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites
Sho Iketani, Seo Jung Hong, Jenny Sheng, et al.
Cell Host & Microbe (2022) Vol. 30, Iss. 10, pp. 1354-1362.e6
Open Access | Times Cited: 48
Pharmacological disruption of mSWI/SNF complex activity restricts SARS-CoV-2 infection
Jin Wei, Ajinkya Patil, Clayton K. Collings, et al.
Nature Genetics (2023) Vol. 55, Iss. 3, pp. 471-483
Open Access | Times Cited: 33
Nirmatrelvir and COVID-19: development, pharmacokinetics, clinical efficacy, resistance, relapse, and pharmacoeconomics
Daniele Focosi, Scott A. McConnell, Shmuel Shoham, et al.
International Journal of Antimicrobial Agents (2023) Vol. 61, Iss. 2, pp. 106708-106708
Open Access | Times Cited: 31
Rapid resistance profiling of SARS-CoV-2 protease inhibitors
Seyed Arad Moghadasi, Rayhan G. Biswas, Daniel A. Harki, et al.
npj Antimicrobials and Resistance (2023) Vol. 1, Iss. 1
Open Access | Times Cited: 30
In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir
Maki Kiso, Yuri Furusawa, Ryuta Uraki, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 29
Strategies for the development and approval of COVID-19 vaccines and therapeutics in the post-pandemic period
Danyi Ao, Xuemei He, Jian Liu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 27
Resistance to nirmatrelvir due to mutations in the Mpro in the subvariants of SARS-CoV-2 Omicron: Another concern?
Srijan Chatterjee, Manojit Bhattacharya, Kuldeep Dhama, et al.
Molecular Therapy — Nucleic Acids (2023) Vol. 32, pp. 263-266
Open Access | Times Cited: 25
Page 1 - Next Page

Scroll to top